CSL Behring enters into gene therapy collaboration with top children's research institute

King of Prussia-based CSL Behring is teaming up with Seattle Children’s Research Institute to develop stem cell gene therapies for primary immunodeficiency diseases. Financial terms of the partnership are being kept confidential. Initially, the alliance will focus on developing gene therapies for patients with Wiskott-Aldrich Syndrome and X-linked agammaglobulinemia. The rare and life-threatening disorders are two of the more than 400 identified primary immunodeficiency diseases in which a part…